Clinical evolution and mortality of critically ill patients with SARS-CoV-2 pneumonia treated with remdesivir in an adult intensive care unit of Paraguay

The health crisis due to Covid-19 led to the search for therapeutics that could improve the evolution of the disease. Remdesivir, an antiviral that interferes with viral replication, was one of the first to be used for the treatment of this pathology. To determine clinical course and mortality of patients with severe SARS-CoV‐2 pneumonia treated with remdesivir, in comparison of those who didn’t receive the medication. Retrospective cohort study, with medical records review of COVID-19 patients, between August 2020 and August 2021. The subjects were divided into two groups, those who received remdesivir before or after admission to intensive care and those who didn’t. The primary outcome variable was mortality in intensive care. Of 214 subjects included, 109 (50,9